Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3% gain. This might have investors contemplating their next move.
Is there a buying opportunity in Supernus Pharmaceuticals, or does it present a risk to your portfolio? Get the full stock story straight from our expert analysts, it’s free.
Why Is Supernus Pharmaceuticals Not Exciting?
Even though the stock has become cheaper, we don’t have much confidence in Supernus Pharmaceuticals. Here are three reasons you should be careful with SUPN, plus one stock we’d rather own.
1. Long-Term Revenue Growth Disappoints
A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Unfortunately, Supernus Pharmaceuticals’s 5.9% annualized revenue growth over the last five years was mediocre. This fell short of our benchmark for the healthcare sector.
2. Fewer Distribution Channels Limit Its Ceiling
Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.
With just $776.9 million in revenue over the past 12 months, Supernus Pharmaceuticals is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.
3. New Investments Fail to Bear Fruit as ROIC Declines
We like to invest in businesses with high returns, but the trend in a company’s ROIC can also be an early indicator of future business quality.
Over the last few years, Supernus Pharmaceuticals’s ROIC has unfortunately decreased. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.
Final Judgment
Supernus Pharmaceuticals isn’t a terrible business, but it doesn’t pass our bar. Following the recent decline, the stock trades at $43.79 per share (or a forward price-to-sales ratio of 2.9×). The market typically values companies like Supernus Pharmaceuticals based on their anticipated profits for the next 12 months, but there aren’t enough published estimates to arrive at a reliable number. You should avoid this stock for now - better opportunities lie elsewhere. Let us point you toward an all-weather company that owns household favorite Taco Bell.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
